pharma · Opioid Use Disorder · Opioid Dependence
Indivior Pty
Indivior Pty Ltd
Indivior is a pharma organization headquartered in Richmond, USA. Primary therapeutic focus areas include Opioid Use Disorder, Opioid Dependence, Schizophrenia, Opioid Dependency, Opiate Dependence. NovaPharmaNews links
., Richmond, VA, US HQ
967 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- ., Richmond, VA, US
- Employees
- 967
- Programs
- 39
- Drugs
- 19
- Patents
- 34
Buprenorphine hydrochloride marketed sublingual tablet (Subutex)
Phase 2 · small molecule · Opioid Dependency
Buprenorphine hydrochloride marketed sublingual tablet (Subutex) for Opioid Dependency is a Phase 2 program (small_molecule) at Indivior Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code P04451
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Indivior Pty Ltd
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Opioid Dependency
- Status
- completed
- Trials
- 1